A Prospective, Randomized, Comparative Study to Evaluate Efficacy of Anticancer Chemotherapy in Predicting Prognosis and Determining Chemotherapy Method in Early Hormone Receptor-positive Breast Cancer Patients With Clinicopathological High Risk and GenesWell™ BCT Low Risk at Multi-center in Korea
A prospective, randomized, comparative study to evaluate efficacy of anticancer chemotherapy in predicting prognosis and determining chemotherapy method in early Hormone Receptor-positive breast cancer patients with clinicopathological high risk and GenesWell™ BCT low risk at multi-center in Korea
• Adult women aged 19-80 at screening
• Histologically invasive carcinoma
• Hormone receptor positive (Estrogen, ER+ and/or Progesterone, PR+)
• Human epidermal growth factor receptor 2 negative (HER2-)
• Axillary lymph node assessment: pN0 or pN1
• Tumor size≥0.5cm
• Clinical high risk (based on modified Adjuvant! Online)
• Patients who agree to genetic testing
• Patients who have adequate organ function
⁃ Genomic low risk (based on GenesWell BCT)
⁃ De novo primary cancer
⁃ Patients how performed surgery with curative aim
⁃ Patients who have provided written informed consent themselves